



**PATENT
MAIL STOP RCE**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re:	Patent Application of David Berd	: Group Art Unit: 1643 : : :
Appln. No.:	09/776,250	: Examiner: Karen A. Canella, Ph.D. : :
Filed:	February 1, 2001	: Attorney Docket No. : 061266-5004-00
For:	LOW DOSE HAPTENIZED TUMOR CELL AND TUMOR CELL EXTRACT IMMUNOTHERAPY	: : :

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §§ 1.97 and 1.98 and to the duty of disclosure set forth in 37 C.F.R. § 1.56, the Examiner in charge of the above-identified application is requested to consider and make of record the references listed on the PTO/SB/08A and PTO/SB/08B submitted herewith. Since the Patent Office has waived the requirement under 37 C.F.R. § 1.98(a)(2)(i) for submitting copies of cited U.S. Patents, the U.S. references are not enclosed.

Although the information submitted herewith may be “material” to the Examiner’s consideration of the subject application, this submission is not intended to constitute an admission that such information is “prior art” as to the claimed invention.

In accordance with 37 C.F.R. § 1.97(g), the filing of this Supplemental Information Disclosure Statement shall not be construed to mean that a search has been made.

This Supplemental Information Disclosure Statement is being filed before the mailing of a first Office Action after the filing of a Request for Continued Examination. Accordingly, no fee is required. 37 C.F.R. 1.97(b)(4).

Respectfully submitted,

April 19, 2007
(Date)

By:

~~DAVID BERD~~

GAIL H. GRIFFIN

Registration No. 51,941

LOUIS W. BEARDELL

Registration No. 40,506

MORGAN, LEWIS & BOCKIUS, LLP

1701 Market Street

Philadelphia, PA 19103-2921

Telephone: (215) 963-5000


Direct Dial: (215) 963-5265

Facsimile: (215) 963-5001

E-Mail: ggriffin@morganlewis.com

Attorneys for Applicants

Enclosures Form PTO/SB/08A (1 page)
 Form PTO/SB/08B (4 pages)
 30 Non-Patent References



INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	5
-------	---	----	---

Application Number	09/776,250
Filing Date	February 1, 2001
First Named Inventor	David Berd
Art Unit	1643
Examiner Name	Karen A. Canella, Ph.D.
Attorney Docket Number	061266-5004-00

[illegible][illegible]


Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2

of

5

Complete if Known

Application Number	09/776,250
Filing Date	February 1, 2001
First Named Inventor	David Berd
Art Unit	1643
Examiner Name	Karen A. Canella, Ph.D.
Attorney Docket Number	061266-5004-00

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		D. Berd et al., U.S. Patent Application No. 08/203,004, filed February 28, 1994.	
		D. Berd et al., U.S. Patent Application No. 08/479,016, filed June 7, 1995.	
		David Berd, U.S. Patent Application No. 08/899,905, filed July 24, 1997.	
		David Berd, U.S. Patent Application No. 08/942,794, filed October 2, 1997.	
		D. Berd et al., U.S. Patent Application No. 09/447,897, filed November 23, 1999.	
		Sato et al., Cancer Invest., 1997;15:98-105.	
		Kim et al., Eur. J. Immunol., 1992;22:775-782.	
		Sherman et al., J. Immunol., 1978;121:1432-1436.	
		Grabbe et al., Immunol. Today, 1995;16:117-121.	
		Siena et al., Exp. Hematol., 1995;23:1463-1471.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/776,250
Filing Date	February 1, 2001
First Named Inventor	David Berd
Art Unit	1643
Examiner Name	Karen A. Canella, Ph.D.
Attorney Docket Number	061266-5004-00

Sheet	3	of	5
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Sahasrabudhe et al., J. Immunol., 1993;151:6302-6310.	
		Shamamian et al., Cancer Immunol. Immunother., 1994;39:73-83.	
		Cox et al., Science, 1994;264:716-719.	
		Peoples et al., J. Immunol., 1993;151:5481-5491.	
		Jerome et al., Cancer Res., 1991;51:2908-2916.	
		Morioka et al., J. Immunol., 1994;153:5650-5658.	
		Burrows et al., J. Neurosci. Res. 1997;49:107-116.	
		Gavin et al., Eur. J. Immunol., 1994;24:2124-2133.	
		Edman et al., Eur. J. Bio-chem., 1967;1:80-91.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO:**

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	09/776,250
Filing Date	February 1, 2001
First Named Inventor	David Berd
Art Unit	1643
Examiner Name	Karen A. Canella, Ph.D.
Attorney Docket Number	061266-5004-00

Sheet	4	of	5
-------	---	----	---

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Kempkes et al., J. Immunol., 1991;147:2467-2473.	
		Jang et al., Eur. J. Immunol., 1991;21:1303-1310.	
		Pistor et al., J. Invest. Dermatol., 1995;105:92-95.	
		Nalefski and Rao, J. Immunol., 1993;150:3806-3816.	
		Carlsson, et al., Biochem J., 1978;173:723-737.	
		Miller et al., J. Immunol., 1976;117:191-196.	
		Brown, "Albumin structure, function and uses", Rosenoer, V.M. et al. (eds.), Pergamon Press:Oxford, pp. 27-51, 1977.	
		Weitkamp, L.R., et al., Ann. Hum. Genet., 1973;37:219-226.	
		Hood et al., "Tolerance and the Regulation of Immunity", Second Edition, 1984, Benjamin-Cummings: Menlo Park, CA, pp. 366-401.	
		McCune et al., Cancer, 1979;43:1619-1623.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.



PTO/SB/08B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known			
		Application Number	09/776,250		
		Filing Date	February 1, 2001		
		First Named Inventor	David Berd		
		Art Unit	1643		
		Examiner Name	Karen A. Canella, Ph.D.		
Sheet	5	of	5	Attorney Docket Number	061266-5004-00

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Pulaski et al., Cancer Res., 1998;58:1486-1493.	
		Berd et al., J. Clin. Oncol., 1997;15:2359-2370.	
		Rennke et al., Kidney International, 1994;45:1044-1056.	
		Heppner et al., Cancer Res. 1978;38:3758-3763.	
		Miller et al., Cancer Res., 1981;41:3863-3867.	
		Miller, Invasion Metastasis, 1981;1:220-226.	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.